Minodronic acid
Names | |
---|---|
Preferred IUPAC name [1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid) | |
Other names Minodronate; YM 529 | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL |
|
ChemSpider |
|
IUPHAR/BPS |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C9H12N2O7P2 |
Molar mass | 322.150 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references |
Chemical compound
Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis.[1] Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.[2]
References
- ^ Shridhar Hegde and Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry. 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.
- ^ Sorbera, L.A.; Castañer, J.; Leeson, P.A. (2002). "Minodronic Acid". Drugs of the Future. 27 (10): 935–941. doi:10.1358/dof.2002.027.10.701186.
- v
- t
- e
Drugs for treatment of bone diseases (M05)
- Nitrogenous
- Non-nitrogenous
- Resorption inhibitor
- Aluminium chlorohydrate
- Dual action bone agent
- RANKL inhibitor
- Sclerostin inhibitor
- Cathepsin K inhibitor
- Parathyroid hormone-related protein analogues
- Calcitonin
- Calcium
- Vitamin D
This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e